Totally agree. That is why a positive 28 readout is so critical, it will confirm that CYP has a commercial product that is safe. Hypothetically, if CYP decides to be a raw-product supplier to Bio-pharma, it would not have to fund any further FDA trials. There are many options open to the company to have early revenue streams. Fuji is just one of many revenue models.
Ann: Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD, page-21
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.16M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 34187 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 21174 | 1 |
View Market Depth
| Last trade - 10.02am 03/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |
Day chart unavailable